Novo Nordisk A/S: Novo Nordisk receives Complete Response Letter in the US for Tresiba(R) and Ryzodeg(R)
February 10, 2013 - Bagsvaerd, Denmark
Company announcement No 11 / 2013:
http://hugin.info/2013/R/1676898/546736.pdf
This announcement is distributed by Thomson Reuters on behalf ofThomson Reuters clients. The owner of this announcement warrants that:(i) the releases contained herein are protected by copyright and other applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Novo Nordisk A/S via Thomson Reuters ONE
[HUG#1676898]
Further information:
Media:
Mike Rulis
+45 3079 3573
Email Contact
Lori Moore
+1 609 919 7991
Email Contact
Investors:
Kasper Roseeuw Poulsen
+45 4442 4303
Email Contact
Frank Daniel Mersebach
+45 4442 0604
Email Contact
Lars Borup Jacobsen
+45 3075 3479
Email Contact
Jannick Lindegaard (US)
+1 609 786 4575
Email Contact
